Breast Cancer News and Research

Latest Breast Cancer News and Research

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it is developing ADCC TherasightTM, a novel theragnostic product that can help guide the drug development process and patient treatment protocols for the cancer therapeutic antibodies that use ADCC (antibody-dependent cellular cytotoxicity) as the major mechanism of action.

12 Nov 2009

Researchers find link between two genes involved in cancer formation in humans

Researchers at Queen's University have found a link between two genes involved in cancer formation in humans, by examining the genes in worms. The groundbreaking discovery provides a foundation for how tumor-forming genes interact, and may offer a drug target for cancer treatment.

11 Nov 2009

OncoVista Innovative Therapies' AdnaTest BreastCancer and EMT1/StemCell products evaluated in German hospitals

OncoVista Innovative Therapies, Inc. reported today that two of its proprietary products, the AdnaTest™ BreastCancer and AdnaTest EMT1/StemCell, were evaluated in Germany by the Departments of Gynecology and Obstetrics and Internal Medicine (Cancer Research) at University Hospital Essen, University of Duisburg-Essen and the Department of Gynecology and Obstetrics, University Hospital of Tuebingen.

11 Nov 2009

Capecitabine in chemotherapy regimen reduces early breast cancer recurrence

An analysis conducted by the Finnish Breast Cancer Group and published in The Lancet Oncology shows women at intermediate to high-risk of early breast cancer recurrence who received capecitabine as part of their chemotherapy regimen had a 34% reduction in the risk of the disease returning or death, compared with those taking the chemotherapy combination regimen without capecitabine.

11 Nov 2009

Poor access to interpreters can compromise doctor-patient communication in cancer care

In a new survey of physicians who treat breast cancer patients, only one-third said they had good access to trained medical interpreters or telephone language-interpretation systems when they needed it. Poor access to interpreters can compromise physician-patient communication that is critically important in cancer care.

11 Nov 2009

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

Peregrine Pharmaceuticals, Inc. today announced that a newly published study shows that a phosphatidylserine (PS)-targeting antibody similar to the company's lead product candidate bavituximab demonstrated potent anti-tumor activity when combined with radiation in a model of aggressive brain cancer, doubling the survival time of test animals and producing long-term cures.

11 Nov 2009

Sprycel holds hope for treating Src dependent ovarian cancer

The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.

11 Nov 2009

Anemia-reducing medications linked to deep vein thrombosis in cancer patients

Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center. The findings will be published online on Nov. 10, 2009 in the Journal of the National Cancer Institute (ahead of the Dec. 2, 2009 print edition).

11 Nov 2009

BioVex completes $70M financing to complete OncoVEX Phase III study

BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has concluded a $70 million private financing, raising $30 million in addition to the $40 million announced in March. The proceeds of the financing will primarily be used to complete the ongoing Phase III pivotal study of OncoVEX (GM-CSF) for the treatment of recurrent and metastatic melanoma and to fund pre-commercialization activities.

10 Nov 2009

SAVI reaches a major milestone in breast brachytherapy

This month marks three years since physicians began offering SAVI™ radiation treatment as part of breast conservation therapy for early-stage breast cancer – a major milestone in breast brachytherapy.

10 Nov 2009

CytRx reports financial results for the three months and nine months ended September 30, 2009

CytRx Corporation, a biopharmaceutical company, today reported financial results for the three months and nine months ended September 30, 2009.

9 Nov 2009

Decision Resources forecasts sales of HER2-targeting agents to grow by 3.3% per year

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2008, human epidermal growth factor receptor 2 (HER2) targeting therapies -- which include Roche/Chugai's Herceptin and GlaxoSmithKline/Nippon Kayaku's Tykerb/Tyverb -- were the highest-selling drug class in breast cancer treatment.

9 Nov 2009

GTx reports financial results for the third quarter of 2009

GTx, Inc. today reported financial results for the third quarter of 2009. The net loss for the third quarter and nine months ended September 30, 2009 was $12.8 million and $35.4 million, respectively, compared with a net loss of $11.9 million and $37.9 million for the same periods in 2008. At September 30, 2009 GTx had cash, cash equivalents and short-term investments of $55.5 million.

9 Nov 2009

Breast Fest Film Festival to focus on storytelling as part of the healing process

After a successful inaugural year, the world's first breast cancer film festival is back and bigger than ever. Along with a new selection of inspiring films that cover the emotional spectrum of the breast cancer journey, Rethink Breast Cancer's 2009 Breast Fest Film Festival is unveiling a new three-day program to include additional workshops to further engage and educate audiences.

9 Nov 2009

Postmenopausal hormone therapy reduces the rate of atypical ductal hyperplasia

The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer.

9 Nov 2009

A divided House approves sweeping health reform legislation, 220-215

After months of intense debate and negotiations, the House of Representatives approved the most ambitious effort ever to change the country's health care system, with 219 Democrats and one Republican voting for the bill and 39 Democrats voting against the bill. Democrats in the chamber cheered the final tally.

9 Nov 2009

Patients with highest breast density have greater risk of cancer recurrence, find researchers

A new study finds that women treated for breast cancer are at higher risk of cancer recurrence if they have dense breasts. Published in the December 15, 2009 issue of Cancer, a peer-reviewed journal of the American Cancer Society, the study's results indicate that breast cancer patients with dense breasts may benefit from additional therapies following surgery, such as radiation.

9 Nov 2009

Current health care debate in the United States complicated

The current health care debate in the United States is complicated. Trade-offs between heath care expenditures, lifestyle choices and life expectancy have been suggested but seldom clearly demonstrated.

7 Nov 2009

Third-quarter 2009 financial results announced by Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the three and nine months ended September 30, 2009.

6 Nov 2009

Positive interim data from the multicenter randomized Phase II trial of palifosfamide presented

ZIOPHARM Oncology, Inc. presented today at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting, positive interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma.

6 Nov 2009

Breast Cancer News and Research

Latest Breast Cancer News and Research

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

Researchers find link between two genes involved in cancer formation in humans

OncoVista Innovative Therapies' AdnaTest BreastCancer and EMT1/StemCell products evaluated in German hospitals

Capecitabine in chemotherapy regimen reduces early breast cancer recurrence

Poor access to interpreters can compromise doctor-patient communication in cancer care

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

Sprycel holds hope for treating Src dependent ovarian cancer

Anemia-reducing medications linked to deep vein thrombosis in cancer patients

BioVex completes $70M financing to complete OncoVEX Phase III study

SAVI reaches a major milestone in breast brachytherapy

CytRx reports financial results for the three months and nine months ended September 30, 2009

Decision Resources forecasts sales of HER2-targeting agents to grow by 3.3% per year

GTx reports financial results for the third quarter of 2009

Breast Fest Film Festival to focus on storytelling as part of the healing process

Postmenopausal hormone therapy reduces the rate of atypical ductal hyperplasia

A divided House approves sweeping health reform legislation, 220-215

Patients with highest breast density have greater risk of cancer recurrence, find researchers

Current health care debate in the United States complicated

Third-quarter 2009 financial results announced by Halozyme Therapeutics

Positive interim data from the multicenter randomized Phase II trial of palifosfamide presented

Industry Focus eBook - Oncology (1st Edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Breast Cancer News and Research

Latest Breast Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in